Abstract. In India, treatment of acute, uncomplicated Plasmodium falciparum malaria is becoming increasingly difficult due to resistance to chloroquine, thus there is a need for new antimalarial drugs. CGP 56697 (co-artemether), a new drug, is a combination of artemether and lumefantrine in a single oral formulation (one tablet ϭ 20 mg of artemether plus 120 mg of lumefantrine). In a double-blind study, 179 patients with acute uncomplicated P. falciparum malaria were randomly assigned to receive either CGP (n ϭ 89) given as a short course of 4 ϫ 4 tablets over a 48-hr period or chloroquine (n ϭ 90) given as four tablets (one tablet ϭ 150 mg of chloroquine base) initially, followed by two tablets each at 6-8, 24, and 48 hr. Due to a death in the chloroquine group and a decrease in the chloroquine cure rate to Ͻ 50% (based on the blinded overall cure rate at that time), recruitment was terminated prematurely. CGP 56697 showed a superior 28-day cure rate (95.4% versus 19.7%; P Ͻ 0.001), time to parasite clearance (median ϭ 36 versus 60 hr; P Ͻ 0.001), and resolution of fever (median ϭ 18 versus 27 hr; P ϭ 0.0456). This drug provides a safe, effective, and rapid therapy for the treatment of acute uncomplicated P. falciparum malaria.
INTRODUCTION
Malaria remains a major health problem worldwide, not least because of development of resistance to currently available therapies. The pattern of malarial resistance varies with geographic location; thus, the standard, first-choice anti-malarial is region-dependent. Recent decades have witnessed the emergence of drug-resistant malarial parasites. Chloroquine-resistant Plasmodium falciparum has now spread to most malarial areas, and has become a significant problem in Southeast Asia. 1 In 1993, a study showed that 5% of the P. falciparum strains in the city of Mumbai (formerly Bombay), India were resistant to chloroquine at the standard total dose of 25 mg base/kg administered over a three-day period. 2 Higher doses (50 mg base/kg) have been tested elsewhere but appear only to delay the onset of recrudescence. 3 In India, the selection of therapy for the treatment of acute, uncomplicated P. falciparum malaria is becoming more difficult due to the increasing resistance of the parasite to chloroquine. 4 CGP 56697 (co-artemether) is an oral, fixed-dose combination of artemether, a derivative of artemisinin, and lumefantrine (benflumetol), a molecule developed by the Academy of Military Medical Sciences in Beijing, People's Republic of China. Artemether has been shown to be beneficial in the treatment of malaria, but recrudescence is common when it is used as a single drug. 5 Lumefantrine is also an effective anti-malarial with a high cure rate, but has the disadvantage of a slow onset of activity. CGP 56697, a single, oral formulation, when given over a 48-hr period, is expected to combine the benefits of both drugs, i.e., fast onset of activity and high cure rate. The safety and efficacy of this combination has been evaluated in several studies of uncomplicated falciparum malaria, and has been shown to be safe and efficacious. 6, 7 The study reported here was designed to compare the efficacy and safety of CGP 56697 with that of standard chloroquine therapy in Indian patients with acute, uncomplicated P. falciparum malaria. Patients with severe or complicated malaria requiring parenteral therapy were excluded from the trial. In spite of the increasing numbers of resistant strains, chloroquine is still recommended by the National Malaria Eradication Program of the Government of India as standard therapy for patients with P. falciparum malaria in India. For this reason, chloroquine was selected as the comparative drug in this trial.
MATERIALS AND METHODS
The study was conducted in Mumbai, India between June 1996 and January 1997. The trial was performed in accordance with the Declaration of Helsinki and its Hong Kong amendment, and according to the principles of good clinical practice, as defined by the Ethics Committee Guidelines and Recommendations 111/397/88-EN. The local Ethics Committee and the Drugs Controller General of India approved the study. Informed consent was obtained from all patients. Written or verbal consent in the presence of a literate witness was obtained from illiterate patients. Written consent was obtained from a parent or legal guardian for patients Ͻ 18 years old.
Trial population. Inclusion. Male and female patients with acute, uncomplicated P. falciparum malaria presenting to the King Edward VII Memorial Hospital in Central Mumbai or the Kasturba Hospital for Infectious Diseases in Mumbai were enrolled into the study if they were at least 16 years old, microscopic examination confirmed a P. falciparum or mixed infection (including a P. falciparum parasitemia Ͼ 1,000 parasites/l), they were willing to comply with the trial protocol, and they provided written informed consent.
Exclusion. Reasons for exclusion were pregnancy/lactation, P. falciparum asexual parasitemia Ͻ 1,000/l or Ͼ 200,000/l, an inability to tolerate oral medication, severe or complicated malaria requiring parenteral treatment, antimalarial treatment within 2 weeks preceding the start of the trial, other investigational drugs taken within 30 days prior to start of the trial, known hypersensitivity or allergy to chloroquine or any artemisinin derivatives, and severe renal, hepatic, cardiac, or nutritional impairment.
Test drugs and treatment randomization. This was a double-blind, double-dummy, randomized, comparative, four-week trial. A computer-generated randomization scheme was used to provide balanced blocks of patient numbers for each treatment. A block size of four was used. Eligible patients were assigned by randomization, in equal numbers, to receive either CGP 56697 or chloroquine. Those randomized to receive CGP 56697 received 4 doses of 4 tablets (each tablet containing 20 mg of artemether and 120 mg of lumefantrine) given at 0, 6-8, 24, and 48 hr. The patients randomized to receive chloroquine received 4 ϩ 2 ϩ 2 ϩ 2 tablets (each tablet containing 150 mg of chloroquine base) given at 0, 6-8, 24, and 48 hr. In addition to trial medication, in accordance with public health policy in India, all patients received a single oral dose of primaquine (45 mg) on day 8 for its gametocytocidal action. Compliance was ensured by administering trial medication under direct supervision of a member of the investigation team. If the patient vomited any of the initial doses within the first hour of administration, these doses were replaced by doses from a duplicate pack. Concomitant medication for chronic illnesses or for any reason during the trial period was recorded and patients who stopped treatment were not replaced. Quality checks for biochemistry were carried out by participation in an external quality control program. Quality checks of peripheral blood smears were carried out by sending slides to a central municipal laboratory.
Trial procedures. All patients fulfilling inclusion and exclusion criteria were hospitalized for 8 days. Day 1 was taken as the day of admission. During this period, each patient underwent a clinical examination and laboratory investigation (including an estimation of glucose-6-phosphate dehydrogenase at baseline) for assessment of safety and efficacy. During the first 72 hr, patients were monitored for parasites by standard methods of blood microscopy and for fever (oral body temperature) at 6-hr intervals. Thereafter, body temperature was measured every 12 hr and blood microscopy performed once a day until day 8. If the malarial parasites were not cleared within seven days, daily measurements were continued until parasite clearance was confirmed. Patients were then seen weekly in the outpatient clinic (days 15, 22, and 29), when blood microscopy was performed and body temperature was measured. If the patient's medical condition during his or her hospital stay deteriorated clinically, if peripheral blood smears showed increasing parasitemia, indicating failure to respond, or if blood films showed the reappearance of P. falciparum on follow-up, rescue medication (quinine, or quinine plus doxycycline, or sulfadoxinepyrimethamine) was initiated as appropriate.
To distinguish recrudescence from new infection, blood samples for a polymerase chain reaction (PCR) were obtained at baseline and on the day of reappearance of parasites, wherever possible. 8, 9 Safety monitoring. This included measurement of vital signs (supine blood pressure and pulse rate) daily until day 8 and then on days 15, 22, and 29 and a 12-lead electrocardiogram recording on days 1, 4, 8, and 29. Laboratory evaluations for hematology (hemoglobin, hematocrit, red blood cells, white blood cells, total, differential, platelets, and reticulocyte counts), clinical chemistry (total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, sodium, potassium, glucose, creatinine, total urea protein, and albumin) and urinalysis (albumin, glucose, bilirubin, and blood by dipstick) were done on days 1, 4, 8, and 29. Patients with abnormal laboratory values were followed regularly until values returned to normal or a valid reason for abnormality was diagnosed.
Since malaria patients typically present with a multitude of nonspecific symptoms, drug-related adverse events are often difficult to identify. During this study, all signs and symptoms were recorded at baseline and during the course of the study to identify treatment-related adverse events. Only those events that worsened during the course of the trial or appeared after baseline were considered for between group analysis.
Efficacy assessment. The primary endpoints of the study were the 28-day cure rate, the time to parasite clearance, and the reduction in parasite load at 24 hr. Secondary end points were the time to resolution of fever and to gametocyte clearance.
The 28-day cure rate was the primary endpoint of therapeutic efficacy in this trial. It is defined as the proportion of patients with clearance of asexual parasitemia within seven days of initiation of treatment, without subsequent recrudescence. The sensitive responses and treatment failures, i.e., RI, RII, and RIII recrudescence were classified as per standard World Health Organization criteria. 10 The time to parasite clearance (PCT) was calculated from the time of administration of the first dose until the first disappearance of asexual parasite forms that was maintained for at least 48 hr. The percentage parasite reduction 24 hr after initiation of treatment was calculated as the number of parasites per microliter at 24 hr compared with that before the first treatment dose.
The fever clearance time (FCT) was defined as the time from first dose until the first time the body temperature decreased to Ͻ 37.5ЊC and remained Ͻ 37.5ЊC for at least an additional 48 hr (only for patients with a temperature Ͼ 37.5ЊC at baseline). It was possible to evaluate only 94 of the 179 patients for the FCT because 85 patients had baseline body temperatures Ͻ 37.5ЊC; 5 patients were censored (measurement stopped) because complete clearance was not reached. Four of these patients received rescue medication for RII/RIII failure; one patient discontinued treatment before maintaining a temperature below 37.5ЊC for at least 48 hr.
The gametocyte clearance time (GCT) was calculated for patients who had gametocytes within the first 72 hr after the start of treatment. It was defined as the time prior to the administration of the first dose of primaquine on day 8 until the first total and continued disappearance of gametocytes that was maintained for at least 48 hr. Patients with RII and RIII resistance to chloroquine were excluded from the analysis for GCT.
Patients with RI resistance received sulfadoxine-pyrimethamine, quinine, or quinine-doxycycline. Since these drugs have no effect on the gametocytes of P. falciparum, data for the presence of gametocytes on day 29 in such patients was also analyzed.
Data sets analyzed. Analysis of the 28-day cure rate was performed for both the intention to treat (ITT) patient population (all randomized patients) and the evaluable patient population. The ITT analysis also included patients who left the study before day 29 due to being lost to follow-up, withdrawing consent, or non-compliance. The latter patients were counted in the ITT analysis as treatment failures.
Patients were considered evaluable for the 28-day cure rate if parasite counts were recorded up to day 29, or the patients showed an unsatisfactory therapeutic effect, i.e., resistance or reappearance of asexual forms of P. falciparum.
Thirty-seven patients did not complete the trial and were either lost to follow-up (n ϭ 33), withdrew consent or were non-compliant (n ϭ 4). One patient received medication for Plasmodium vivax malaria and was also discontinued. These 38 patients were not included in the 28-day cure-rate determination in evaluable patients (24 who were treated with CGP 56697 and 14 who were treated with chloroquine). There was no significant difference in the number of dropouts in each of the two groups.
The PCT was analyzed in the ITT population (n ϭ 179). The time to parasite clearance was censored at the last parasite measurement if clearance had not been reached and/or rescue antimalarials had been given for RII or RIII. Thirteen patients met these criteria: 12 patients because they were receiving chloroquine for RII or RIII treatment failures and another patient receiving CGP 56697 who left the hospital against medical advice without confirmed negativity for P. falciparum for at least 48 hr.
Parasite reduction at 24 hr was evaluated in all patients for whom relevant data were available (n ϭ 178), i.e., excluding a patient who received chloroquine and had an RIII treatment failure.
Statistical methods. A sample size of 252 was recruited based on the assumption of a 28-day cure rate of 95% for CGP 56697 and 80% for chloroquine (␣ ϭ 5%, power ϭ 90%, using the method of Casagrandes, and anticipating a 10% dropout rate within 28 days).
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For each 28-day cure rate, 95% confidence intervals were calculated using Pearson-Clopper limits. The difference between treatments was tested using Fisher's exact test. Median, inter-quartile range, and 95% confidence intervals for the median were calculated for the PCT and the FCT using the Kaplan-Meier method. Treatment effect was tested using the Wilcoxon test.
The prognostic influence of selected baseline characteristics (baseline parasite density, previous infection, center, baseline temperature, sex, age, and weight) and the influence of these variables on the PCT and FCT were examined using Cox proportional hazard regression. The influence of these characteristics on the 28-day cure rate was evaluated using logistic regression.
RESULTS
All data recorded on the case record forms were subjected to 100% source data verification.
Patients. A total of 179 of the originally recruited 252 patients were enrolled in the study. Recruitment was terminated prematurely because the overall cure rate with chloroquine decreased to 50%, indicating a higher degree of chloroquine resistance than originally assumed.
Overall, 37 patients left the trial for the following reasons: lost to follow-up, withdrew consent, and non-compliance. An additional patient received rescue medication for P. vivax malaria and also left the study. These 38 patients were not included in the 28-day cure-rate determination (24 treated with CGP 56697 and 14 treated with chloroquine). There were 63 premature withdrawals from the study because of an unsatisfactory therapeutic response: 3 (3.4%) patients in the group receiving CGP 56697 and 60 (66.6%) receiving chloroquine. One patient receiving chloroquine died.
Most (n ϭ 57) of the treatment failures received sulfadoxine-pyrimethamine (single dose of 3 tablets), or in exceptional cases (n ϭ 9), quinine alone or in combination with doxycycline.
The characteristics of patients at baseline are shown in Tables 1 and 2 . There were no significant differences between the two treatment groups, including the duration of illness.
Twenty-eight-day cure rate. In the CGP 56697 treatment group, only three of the 65 evaluable patients experienced a reappearance of parasites, one each on days 22, 29, and 30, and there were no RII or RIII treatment failures. Of the 76 evaluable patients treated with chloroquine, 49 experienced RI failures, 8 had RII failures, and 4 had RIII failures, with a time-to-parasite reappearance between seven and 29 days (Table 3 ).
In the evaluable patient population, the 28-day cure rate of 95.4% (62 of 65 patients) for those treated with CGP 56697 was significantly higher than the 19.7% rate (15 of 76 patients) for those treated with chloroquine (P Ͻ 0.001). There was also a significant difference in the cure rates when the ITT population was considered: 69.7% (62 of 89 patients) versus 16.7% (15 of 90 patients) ( Table 3 ). An exploratory adjusted analysis using logistic regression indicated that none of the baseline characteristics (parasite density, 
Ͻ0.001
* CI ϭ confidence interval; ITT ϭ intention to treat; PCT ϭ parasite clearance time; FCT ϭ fever clearance time; GCT ϭ gametocyte clearance time.
temperature, age, sex, weight, previous malaria infection, or center) had a significant effect on this outcome. Time to parasite clearance. The PCT was significantly shorter for patients receiving CGP 56697 than for those receiving chloroquine (Table 3) ; median clearance time ϭ 36 hr and 60 hr, respectively (P Ͻ 0.001).
An exploratory adjusted analysis showed that parasite density and body temperature at baseline influenced the PCT. A high parasite density (P Ͻ 0.001) and high body temperature (P ϭ 0.0799) lowered the estimated probability of reaching parasite clearance. Nevertheless, after adjusting for these characteristics, the difference in treatment effects remained highly significant when CGP 56697 was compared with chloroquine (P Ͻ 0.001).
Fifteen patients in the group receiving CGP 56697 presented with a parasite density Ͼ 15,000/l at baseline ( Table  2 ). The median PCT (36 hr) for these patients was identical to that of the entire group receiving CGP 56697. For the 18 patients in the group receiving chloroquine with a parasite density Ͼ 15,000/l at baseline (Table 2) , the median PCT (96 hr) was much longer than that of the entire group receiving chloroquine (60 hr). However, of these 18 patients receiving chloroquine, 12 failed treatment (5 RI, 4 RII, and 3 RIII failures), three were lost to follow-up within two weeks, and only three patients were cured.
Parasite reduction at 24 hr. Parasite reduction at 24 hr in the group receiving CGP 56697 was higher than that in the group receiving chloroquine; median values ϭ 98.8% and 70.7%, respectively (P Ͻ 0.001) ( Table 3) . None of the patients receiving CGP 56697 had a higher parasite count 24 hr after the start of treatment than that at baseline, whereas 18 patients receiving chloroquine still had a higher count than at baseline.
Time to fever clearance. The time taken for resolution of fever was significantly lower in patients who received CGP 56697 than in those who received chloroquine; median values ϭ 18 hr and 27 hr, respectively (P ϭ 0.0456) ( Table  3 ). An exploratory adjusted analysis using Cox's proportional hazard regression demonstrated that high parasite density at baseline increased the FCT (P ϭ 0.0019). Furthermore, patients with a previous infection had a higher estimated probability of having fever clearance (P ϭ 0.06). When adjusted for the baseline characteristics, the difference in treatment effects was statistically significant in favor of CGP 56697 (P ϭ 0.007).
Gametocytemia. At pretreatment (day 1), 25 (28.4%) patients in the group receiving CGP 56697 and 25 (32.5%) patients in the group receiving chloroquine had gametocytes detected in the peripheral blood. Fifty-one (57.3%) patients receiving CGP 56697 and 57 (73.1%) receiving chloroquine had gametocytes detected at any time within the first 72 hr (evaluable patients for the time to gametocyte clearance). Of these patients, 13 (25.5%) receiving CGP 56697 and 43 (74.4%) receiving chloroquine still had gametocyte-positive slides on day 8 prior to receiving 45 mg of primaquine (Table 4). Their time was censored at the last measurement point if clearance had not been reached just prior to primaquine administration. The median GCT for the group receiving CGP 56697 was 120 hr, whereas less than 25% of the patients receiving chloroquine showed gametocyte clearance within the first week. This difference was statistically significant (P Ͻ 0.001).
At follow-up, all patients receiving CGP 56697 were negative for gametocytes on day 29, while 68.8% of the patients receiving chloroquine were positive on day 29 (excluding patients with RII and RIII failures, but including all slides, even after sulfadoxine-pyrimethamine or quinine was given).
Results of the PCR. A total of 54 paired samples from both groups were evaluable for the PCR. There was a reappearance of P. falciparum in the blood of three patients receiving CGP 56697 and 49 patients receiving chloroquine. Forty-two of the 49 patients in the group receiving chloroquine were evaluated by the PCR; 2 were classified as new infections while the remainder were shown to be recrudescences. The PCR could not be done for three patients in the group receiving CGP 56697 due to failure to amplify in one case; no samples were available in the other two. Thus in the CGP group, PCR was actually performed on only one patient sample which failed to amplify. All three were classified as recrudescences.
Safety results. A high percentage of patients in both treatment groups presented with signs and symptoms typical of malaria such as headache (61%), splenomegaly (55%), fatigue (49%), rigors (46%), anorexia (40%), hepatomegaly (29%), dizziness (25%), vomiting (26%), and abdominal pain (19%). In both groups, baseline malarial symptoms resolved rapidly with treatment, with resolution of rigors and vomiting being faster than resolution of anorexia, headache, and fatigue. One patient in the group receiving chloroquine died. This death was due to cardiorespiratory arrest following cerebral malaria and was not thought to be related to the trial medication. No other serious adverse events were reported. None of the patients stopped treatment due to adverse events and/ or abnormalities in laboratory test results.
The number of patients for whom adverse events were recorded during the time period after baseline but before recrudescence was 43.6% in the group receiving CGP 56697 compared with 60% in the group receiving chloroquine. Adverse events are shown in Table 4 . The incidence of vomiting and pruritus was lower in the group receiving CGP 56697.
Median electrocardiographic values for QTc did not change in either treatment group over the course of the trial. The QTc values, which were measured manually by the investigator, were generally very high. At baseline, 7 patients receiving CGP 56697 and 12 patients receiving chloroquine had QTc values Ͼ 450 msec (up to 580 msec, overall median in both treatment groups ϭ 410 msec.). For all patients receiving CGP 56697, the QTc values decreased after baseline, except in two patients who only had a slight increase of 2%. In the group receiving chloroquine, seven of the 12 patients had decreased or stable QTc values, whereas the other five patients had increased QTc values to Ͼ 500 msec. An increase of the QTc value Ͼ 30 msec with a value Ͼ 430 msec for males or 450 for females during the first week after the start of treatment was seen in only five (5.7%) patients receiving CGP 56697 and in 10 (11.2%) patients receiving chloroquine. No other clinical cardiac symptoms or signs were recorded at any time during the trial for any of the other trial patients.
The white blood cell count changes over the course of the trial reflected changes typical of malaria. Leukopenia at presentation resolved slightly quicker in the group receiving CGP 56697 than in the group receiving chloroquine. All other hematologic values remained essentially constant and were not significantly altered during the trial. Baseline platelet counts were low in both treatment groups but tended to increase with disease resolution, as has been previously reported. 12 A rebound effect was particularly evident on day 8 in the patients treated with CGP 56697. Liver and kidney function test results showed no significant changes other than those related to disease resolution over course of treatment. The results of urine tests (albumin, bilirubin, blood, and glucose) showed no changes from baseline other than a tendency toward normalization.
DISCUSSION
In this study, CGP 56697 given as four doses of four tablets over a 48-hr period was well tolerated and highly efficacious in patients with acute, uncomplicated malaria.
The expectation that artemether would produce a rapid reduction of parasites during the initial stages of treatment, and that lumefantrine (benflumetol) would then prevent reappearance during the follow-up period was well supported by the efficacy data, with a median PCT of 36 hr and concomitant resolution of fever (median FCT ϭ 18 hr). There was also a rapid clearance of gametocytes (median GCT ϭ 120 hr), with almost half (45.1%) of the patients receiving CGP 56697 showing gametocyte clearance within the first 96 hr. The cure rate after 28 days for those receiving CGP 56697 was 95.4% among patients who completed the trial. Patients who received CGP 56697, even those with parasite densities Ͼ 15,000/l at baseline, had equally rapid clearance of parasitemia (36 hr). However, patients with parasite densities Ͼ 15,000/l who received chloroquine had long median PCTs (96 hr), with more patients in this group having RII and RIII resistance, compared with a median PCT of 60 hr in the entire group. Various parameters (28-day cure rate in the ITT and in evaluable patients, time to parasite clearance, parasite reduction at 24 hr, time to fever clearance in evaluable patients) were significantly better in the group receiving CGP 56697 than in the group receiving chloroquine.
This trial was terminated prematurely following the death of one patient in the group receiving chloroquine. At this time, the overall (blinded) cure rate was approximately 50%, an observation that reinforced the original premise that resistance to chloroquine constituted a very serious problem, and that the requirement for a new anti-malarial was paramount. Although chloroquine remains the standard treatment for acute uncomplicated P. falciparum malaria in this region of India, the low efficacy rate observed argues against the suitability of chloroquine as a comparative drug in this study. However, chloroquine was chosen based on our observations of sensitivity to this drug in 1993. 2 Selection of patients with parasite counts Ͼ 1,000/l and the inclusion of an infectious diseases hospital that gets referrals from more distant areas may be the reason for the observed higher incidence of chloroquine resistance compared with our earlier observations. Not surprisingly, CGP 56697 proved superior to chloroquine with respect to all efficacy and safety variables measured.
Recent studies have focused attention on effect of artemisinin derivatives on gametocytes. 13 Artemisinin derivatives do not kill mature gametocytes of P. falciparum, but prevent development of gametocytes by their activity against young and mature asexual stage parasites (precursors of the sexual stage) and also early stage I-III gametocytes. In the group treated with CGP 56697, gametocytes were absent from 83.3% of the patients before treatment with primaquine and from 100% of the patients on day 29. Thus, CGP 56697 has the potential to inhibit disease transmission by reducing the reservoir of infection, an important consideration in the treatment of P. falciparum malaria. 13 In a separate study of patients with malaria caused by P. falciparum sensitive to chloroquine, we have shown that gametocytes are present despite treatment with a supervised dose (45 mg) of primaquine and undergo exflagellation ex vivo, indicating viability. 14 This indicates the inefficiency of this dose of primaquine as a gametocytocidal agent.
There were no serious adverse events or abnormal laboratory findings other than those usually associated with acute malarial infection. The adverse events recorded after baseline and before recrudescence were lower in the group treated with CGP 56697 than in those treated with chloroquine.
In conclusion, this study shows that CGP 56697 (combination of artemether and lumefantrine) is a well-tolerated, effective, and rapid treatment in adults for acute uncomplicated P. falciparum malaria. This drug could prove to be an alternative treatment for malaria in India given the decrease in sensitivity to chloroquine.
